$13.84
Today
as of Sep 4, 16:49 ET
Last 30 days
Recent Press Releases & News
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study
Overview
52-week range
$4.79
$26
43% of range
Avg surprise (last 3)
+109.5%
Avg reaction (last 2)
+3.4%
50% positive
Latest IV / EM
150%
EM ±23.5% · $15 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.45 | $-0.28 | -60.7% | -178.9% | -2.8% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $-0.15 | $-0.31 | +51.6% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $0.57 | $-0.24 | +337.5% | — | +9.6% | earnings |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $4M | — | $13M | $23M | $85M | — | $9M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-49M | $-50M | — | $-33M | $-16M | $44M | — | $-27M |
| Net income | $-43M | $-45M | — | $-27M | $-12M | $47M | — | $-24M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $90M | $160M | $130M | $208M | $69M | $79M | $224M | $126M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $631M | $678M | $393M | $402M | $299M | $332M | $377M | $251M |
| Total assets | $691M | $736M | $449M | $460M | $360M | $393M | $439M | $315M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $204M | $215M | $216M | $214M | $92M | $118M | $216M | $110M |
| Total equity | $487M | $522M | $233M | $246M | $268M | $275M | $223M | $205M |